In this week's PLoS Medicine, Christian Lienhardt from the WHO in Geneva, Switzerland and colleagues announce that the Stop TB Partnership and the WHO Stop TB Department have launched the TB Research Movement.

Peru has 37% of all multi-resistant tuberculosis cases in the Americas and one in four patients of the disease abandon medication in a mild stage of the disease according to the World Health Organization.

Concomitant rifampicin-containing tuberculosis treatment reduced apparent efavirenz clearance with a corresponding increase in efavirenz exposure.

The MEC for Health Dr Sibongiseni Dhlomo invites the media to the World AIDS Day commemoration where he would be outlining government's Provincial Strategic Plan 2012 - 2016, highlight issues around disability and HIV as well as launch the Men's Forum in Amajuba.

After Chinese mobile phones and toys, it’s the serological test kits from the Dragon that are flooding the Indian market. But more importantly, they are being commercially used rampantly by private medical practitioners to diagnose tuberculosis (TB) in violation of WHO guidelines.

Menlo Park, Calif. — November 29, 2011 — In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

Scientists at the John Innes Centre led by Dr Stephen Bornemann and Dr Dave Lawson have worked out the structure of a class of enzyme that has been genetically validated as a new drug target in Mycobacterium tuberculosis, a pathogenic bacterium which is responsible for 2 million tuberculosis deaths worldwide each year. The scientists have been awarded over £500,000 by the Biotechnology and Biological Sciences Research Council (BBSRC) to work out how this enzyme works and is regulated, which will help in the development of new therapies against tuberculosis.

28 November 2011 - Geneva - The Stop TB Partnership's Global Drug Facility (GDF) is inviting applications for its twenty-sixth round of grants.

On a windy Monday morning in Western Kenya, Theresia Anyango and her one-year baby Jeff Otieno calmly follows a counseling session taking place at the Siaya health center.

A group of Hyderabad scientists has discovered a novel lead molecule that could effectively kill the bacteria that cause tuberculosis, while another group has found that the TB strains circulating in Hyderabad and other parts of Andhra Pradesh are of “ancestral” type and, thus, relatively less damaging in nature.